Corbus Pharmaceuticals Holdings Inc. on Monday announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug, Resunab, designed for the treatment of diffuse cutaneous systemic sclerosis. Read More »

Titan Pharmaceuticals Inc. on Monday announced the resubmission by Braeburn Pharmaceuticals of a New Drug Application to the U.S. Food and Drug Administration for Probuphine. Read More »

UT Southwestern Medical Center President Daniel K. Podolsky and faculty members recently joined U.S. Reps. Michael C. Burgess (R-TX) and Joe Barton (R-TX) in a roundtable discussion on the 21st Century Cures Act. Read More »

AstraZeneca recently announced a collaboration agreement with Valeant Pharmaceuticals International Inc., under which it will grant an exclusive license for Valeant to develop and commercialize brodalumab. Read More »

BioMarin Pharmaceutical Inc. on Monday announced they will present data in two oral and 19 poster presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting being held today until Sept. 4 in Lyon, France. Read More »

Advaxis Inc. announced on Tuesday that its final clinical data from Stage 1 of the ongoing two-stage Phase 2 study of axalimogene filolisba in patients with persistent or recurrent metastatic carcinoma of the cervix will be presented at the American Gynecological & Obstetrical Society's annual meeting. Read More »

Diamyd Medical announced Monday that it has entered into an exclusive license agreement for using the gluten protein gliadin for the treatment and prevention of type 1 diabetes. Read More »

Gregory MacMichael and Howard B. Johnson named new vice presidents Read More »

Trial to test SGX942, a first-in-class innate defense regulator for use with head and neck cancers. Read More »

TeaserPharmacy-based patient care solutions provider Ateb, Inc. recently launched its first-ever branding campaign, "Driving Healthy Outcomes for Patients, Pharmacies, and Payers."HeadlineAteb launches branding campaignBodyThe campaign's aim is to develop innovative patient engagement solutions. Read More »

Greatbatch, Inc. announced Thursday it has entered into a definitive agreement to acquire Lake Region Medical for around $1.73 billion in cash and stock. Read More »

The American College of Rheumatology's The Lupus Initiative (TLI) announced Tuesday the award of a one-year, $500,000 grant from the Office of Minority Health to expand its national education program. Read More »

Portola Pharmaceuticals announced Thursday that the results of a preclinical study of andexanet alfa will be presented in a moderated poster session at the European Society of Cardiology 2015 Congress in London on Aug. 31 at 10:51 a.m. Read More »

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced Thursday it has filed clinical trial applications with the UK, German and Austrian regulatory agencies for IV rigosertib as a treatment in higher-risk myelodysplastic syndromes patients after failure of a hypomethylating agent therapy. Read More »

Tocagen, Inc. announced Tuesday that the U.S. Food and Drug Administration has granted orphan drug designation to the company's lead immuno-oncology product candidate, Toca 511 & Toca FC, for the treatment of glioblastoma. Read More »

Valeant Pharmaceuticals International, Inc. announced Tuesday the addition of D. Robert Hale, partner of ValueAct Capital, to its board of directors and the resignation of Jeffrey W. Ubben, CEO and CIO of ValueAct Capital, effective as of Aug. 19. Read More »

Regulus Therapeutics, Inc., a biopharmaceutical company, announced Tuesday the appointment of Michael Huang as vice president of clinical development. Read More »

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced Tuesday it will be presenting at the 17th annual Rodman & Renshaw Global Investment Conference from Sept. 9-10 at the St. Regis Hotel in New York. Read More »

Recent partnership promises cheaper access to prescription drugs. Read More »

Sarepta Therapeutics Inc., a developer of RNA-targeted therapeutics, on Tuesday announced that the U.S. Food and Drug Administration (FDA) has filed the New Drug Application for eteplirsen for the treatment of Duchenne muscular dystrophy amenable to exon 51 skipping. Read More »